206 related articles for article (PubMed ID: 16932322)
41. Long-term IGF-I treatment of children with Laron syndrome increases adiposity.
Laron Z; Ginsberg S; Lilos P; Arbiv M; Vaisman N
Growth Horm IGF Res; 2006 Feb; 16(1):61-4. PubMed ID: 16442822
[TBL] [Abstract][Full Text] [Related]
42. Mecasermin rinfabate: rhIGF-I/rhIGFBP-3 complex: iPLEX.
Williams RM; McDonald A; O'Savage M; Dunger DB
Expert Opin Drug Metab Toxicol; 2008 Mar; 4(3):311-24. PubMed ID: 18363546
[TBL] [Abstract][Full Text] [Related]
43. Further observations on the effects of long-term treatment with recombinant human insulin-like growth factor 1 in growth hormone insensitivity syndrome.
El Kholy M; Amr NH; Elsedfy H
Horm Res Paediatr; 2014; 81(4):258-65. PubMed ID: 24642532
[TBL] [Abstract][Full Text] [Related]
44. Abnormal growth in noonan syndrome: genetic and endocrine features and optimal treatment.
Padidela R; Camacho-Hübner C; Attie KM; Savage MO
Horm Res; 2008; 70(3):129-36. PubMed ID: 18663312
[TBL] [Abstract][Full Text] [Related]
45. Development and biological function of the female gonads and genitalia in IGF-I deficiency -- Laron syndrome as a model.
Laron Z
Pediatr Endocrinol Rev; 2006 Jan; 3 Suppl 1():188-91. PubMed ID: 16641857
[TBL] [Abstract][Full Text] [Related]
46. The role of recombinant insulin-like growth factor I in the treatment of the short child.
Rosenbloom AL
Curr Opin Pediatr; 2007 Aug; 19(4):458-64. PubMed ID: 17630612
[TBL] [Abstract][Full Text] [Related]
47. IGF-I replacement therapy in children with congenital IGF-I deficiency (Laron syndrome) maintains heart dimension and function.
Scheinowitz M; Feinberg MS; Laron Z
Growth Horm IGF Res; 2009 Jun; 19(3):280-2. PubMed ID: 19117781
[TBL] [Abstract][Full Text] [Related]
48. Congenital growth hormone insensitivity syndromes and their relevance to idiopathic short stature.
Clayton PE; Freeth JS; Norman MR
Clin Endocrinol (Oxf); 1999 Mar; 50(3):275-83. PubMed ID: 10435051
[No Abstract] [Full Text] [Related]
49. The E180splice mutation in the GHR gene causing Laron syndrome: witness of a Sephardic Jewish exodus from the Iberian Peninsula to the New World?
Gonçalves FT; Fridman C; Pinto EM; Guevara-Aguirre J; Shevah O; Rosembloom AL; Hwa V; Cassorla F; Rosenfeld RG; Lins TS; Damiani D; Arnhold IJ; Laron Z; Jorge AA
Am J Med Genet A; 2014 May; 164A(5):1204-8. PubMed ID: 24664892
[TBL] [Abstract][Full Text] [Related]
50. Recombinant human insulin-like growth factor-I therapy for children with growth disorders.
Richmond EJ; Rogol AD
Adv Ther; 2008 Dec; 25(12):1276-87. PubMed ID: 19066756
[TBL] [Abstract][Full Text] [Related]
51. Statement 3: a low serum IGF-I Level in idiopathic short stature patients indicates partial GH insensitivity.
Bang P
Pediatr Endocrinol Rev; 2008 Apr; 5 Suppl 3():841-6. PubMed ID: 18438327
[No Abstract] [Full Text] [Related]
52. Oral and dental findings in a child with growth hormone insensitivity syndrome.
Abanto J; Celiberti P; Alves FB; Rossier V; Vieira SA; Ciamponi AL; Raggio DP
J Dent Child (Chic); 2010; 77(1):54-8. PubMed ID: 20359431
[TBL] [Abstract][Full Text] [Related]
53. Laron syndrome - A historical perspective.
Laron Z; Werner H
Rev Endocr Metab Disord; 2021 Mar; 22(1):31-41. PubMed ID: 32964395
[TBL] [Abstract][Full Text] [Related]
54. Indications, limitations and pitfalls in the determination of human growth hormone, IGF-I and their binding proteins.
Laron Z; Bidlingmaier M; Strasburger CJ
Pediatr Endocrinol Rev; 2007 Oct; 5 Suppl 1():555-69. PubMed ID: 18167466
[TBL] [Abstract][Full Text] [Related]
55. IGF-I treatment of patients with Laron syndrome suppresses serum thrombopoietin levels but does not affect serum erythropoietin.
Orit S; Joanne Y; Meira Z; Hannah T; Zvi L
Am J Hematol; 2009 Jan; 84(1):64. PubMed ID: 19021123
[No Abstract] [Full Text] [Related]
56. Effectiveness and safety of rhIGF1 therapy in patients with or without Laron syndrome.
Bang P; Woelfle J; Perrot V; Sert C; Polak M
Eur J Endocrinol; 2021 Feb; 184(2):267-276. PubMed ID: 33434161
[TBL] [Abstract][Full Text] [Related]
57. [Human insulin-like growth factor I and treatment in diabetes].
Koivisto VA
Duodecim; 1994; 110(23-24):2197-201. PubMed ID: 8654239
[No Abstract] [Full Text] [Related]
58. Growth hormone insensitivity (Laron syndrome).
Laron Z
Rev Endocr Metab Disord; 2002 Dec; 3(4):347-55. PubMed ID: 12424436
[No Abstract] [Full Text] [Related]
59. Comparative skeletal features between Homo floresiensis and patients with primary growth hormone insensitivity (Laron Syndrome).
Hershkovitz I; Kornreich L; Laron Z
Am J Phys Anthropol; 2007 Oct; 134(2):198-208. PubMed ID: 17596857
[TBL] [Abstract][Full Text] [Related]
60. IGF-I deficiency, longevity and cancer protection of patients with Laron syndrome.
Laron Z; Kauli R; Lapkina L; Werner H
Mutat Res Rev Mutat Res; 2017; 772():123-133. PubMed ID: 28528685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
